Published in Int J Oncol on November 14, 2012
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs (2013) 0.94
Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition. PLoS One (2013) 0.89
Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol (2014) 0.89
Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocr Relat Cancer (2015) 0.89
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget (2013) 0.88
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs (2014) 0.87
Androgen receptor variation affects prostate cancer progression and drug resistance. Pharmacol Res (2016) 0.87
Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharm Dev Technol (2014) 0.79
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells. Cancers (Basel) (2015) 0.79
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer (2016) 0.77
Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clin Cancer Res (2016) 0.76
The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus. PLoS One (2015) 0.75
Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52. Mol Oncol (2017) 0.75
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leuk Res (2015) 0.75
Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel) (2016) 0.75
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells. Mol Pharmacol (2016) 0.75
Hsp70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells. Cancer Sci (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev (1997) 6.71
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Heat shock protein 90: the cancer chaperone. J Biosci (2007) 3.05
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell (2009) 2.85
AR, the cell cycle, and prostate cancer. Nucl Recept Signal (2008) 2.44
Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol (2008) 2.41
Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem (2009) 2.34
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res (2011) 2.25
Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem (1996) 2.15
Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res (2007) 2.06
Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res (2009) 1.96
Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res (1997) 1.95
Development and application of Hsp90 inhibitors. Drug Discov Today (2007) 1.91
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res (2006) 1.90
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem (2003) 1.80
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther (2011) 1.74
Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol (2008) 1.57
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
Repressors of androgen and progesterone receptor action. J Biol Chem (2003) 1.35
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One (2011) 1.31
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 1.27
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem (2005) 1.25
Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones (2002) 1.24
Hsp90 is a core centrosomal component and is required at different stages of the centrosome cycle in Drosophila and vertebrates. EMBO J (2000) 1.23
The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate (2007) 1.20
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer (2011) 1.17
A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) Mol Endocrinol (1999) 1.10
The Hsp90 chaperone machinery: from structure to drug development. BMB Rep (2009) 1.10
Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res (2004) 1.08
Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol (2011) 1.07
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology (2011) 1.06
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs (2012) 1.03
A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res (2011) 1.00
Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. J Biol Chem (2011) 0.94
The IGF axis in prostate cancer. Curr Pharm Des (2007) 0.93
Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate (1991) 0.92
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate (2011) 0.89
Emerging novel therapies for advanced prostate cancer. Ther Adv Urol (2012) 0.87
HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr Med Chem (2009) 0.86
Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res (2005) 2.14
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A (2009) 2.11
Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res (2006) 1.90
Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem (2006) 1.85
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A (2006) 1.78
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther (2011) 1.74
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63
International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev (2006) 1.60
Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol (2003) 1.51
Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol (2005) 1.41
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci U S A (2004) 1.39
Repressors of androgen and progesterone receptor action. J Biol Chem (2003) 1.35
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35
Photosynthetic responses of corn and soybean to foliar application of salicylates. J Plant Physiol (2003) 1.32
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One (2011) 1.31
Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem (2006) 1.31
Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther (2013) 1.28
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res (2012) 1.26
Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol (2005) 1.25
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther (2012) 1.22
Development and implementation of a database system to manage a large-scale mouse ENU-mutagenesis program. Mamm Genome (2004) 1.14
Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. Biofactors (2009) 1.13
Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS One (2012) 1.12
Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol (2008) 1.12
Isolation of plant-growth-promoting Bacillus strains from soybean root nodules. Can J Microbiol (2002) 1.10
CVD growth of large area smooth-edged graphene nanomesh by nanosphere lithography. Sci Rep (2013) 1.09
Implementation of the modified-SHIRPA protocol for screening of dominant phenotypes in a large-scale ENU mutagenesis program. Mamm Genome (2005) 1.08
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate (2005) 1.06
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther (2014) 1.04
Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol (2008) 1.03
Chitosan and chitin oligomers increase phenylalanine ammonia-lyase and tyrosine ammonia-lyase activities in soybean leaves. J Plant Physiol (2003) 1.03
A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab (2004) 1.03
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs (2012) 1.03
Coactivator selective regulation of androgen receptor activity. Steroids (2009) 1.02
p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology (2003) 1.00
Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids (2013) 0.99
1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology (2009) 0.99
Vitamin D and prostate cancer. Exp Biol Med (Maywood) (2004) 0.99
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood (2010) 0.98
Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s). J Biol Chem (2003) 0.97
Vitamin D and prostate cancer. J Androl (2002) 0.97
The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem (2004) 0.96
Nod factor [Nod Bj V (C(18:1), MeFuc)] and lumichrome enhance photosynthesis and growth of corn and soybean. J Plant Physiol (2008) 0.96
Plant light interception can be explained via computed tomography scanning: demonstration with pyramidal cedar (Thuja occidentalis, Fastigiata). Ann Bot (2007) 0.96
Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids (2007) 0.95
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs (2013) 0.94
Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res (2009) 0.94
c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol (2005) 0.93
Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res (2013) 0.92
Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. Blood (2010) 0.91
Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate (2005) 0.91
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res (2004) 0.91
Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem (2005) 0.91
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat (2014) 0.90
Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease. Proc Natl Acad Sci U S A (2013) 0.90
Novel phosphorylation target in the serum response factor MADS box regulates alpha-actin transcription. Biochemistry (2003) 0.90
Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J (2006) 0.90
EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther (2009) 0.90
Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol (2012) 0.89
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. Clin Cancer Res (2013) 0.89
1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology (2010) 0.88
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res (2013) 0.88
Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Angiogenesis (2013) 0.88
Constitutively active FOXO1a and a DNA-binding domain mutant exhibit distinct co-regulatory functions to enhance progesterone receptor A activity. J Mol Endocrinol (2007) 0.88
Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids (2005) 0.87
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs (2014) 0.87